- Home
- NVO vs APP Comparison
NVO vs APP Comparison
Compare NVO & APP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVO | APP |
|---|---|---|
| Founded | 1923 | 2012 |
| Country | Denmark | United States |
| Employees | 69500 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.4B | 166.9B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NVO | APP |
|---|---|---|
| Price | $43.02 | $475.49 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 18 |
| Target Price | $51.00 | ★ $694.44 |
| AVG Volume (30 Days) | ★ 10.9M | 4.7M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.19% | N/A |
| EPS Growth | N/A | ★ 115.23 |
| EPS | N/A | ★ 3.56 |
| Revenue | N/A | ★ $5,480,717,000.00 |
| Revenue This Year | N/A | $47.88 |
| Revenue Next Year | $3.70 | $29.14 |
| P/E Ratio | ★ $13.60 | $134.61 |
| Revenue Growth | N/A | ★ 16.38 |
| 52 Week Low | $35.12 | $321.68 |
| 52 Week High | $71.80 | $745.61 |
Technical Indicators
Market Signals| Indicator | NVO | APP |
|---|---|---|
| Relative Strength Index (RSI) | 47.82 | 42.35 |
| Support Level | $41.05 | $362.60 |
| Resistance Level | $50.30 | $499.42 |
| Average True Range (ATR) | 1.37 | 32.18 |
| MACD | -0.08 | -11.41 |
| Stochastic Oscillator | 46.61 | 9.81 |
Price Performance
Historical ComparisonAbout NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
About APP Applovin Corporation
AppLovin is a vertically integrated advertising technology company that acts as a demand-side platform for advertisers, a supply-side platform for publishers, and an exchange facilitating transactions between the two. About 80% of AppLovin's revenue comes from the DSP, AppDiscovery, while the remainder comes from the SSP, Max. AppLovin's primary tool for future growth is AXON 2, which is an ad optimizer operating within the DSP that allows advertisers to place ads according to specified return thresholds.